Navigation Links
Align Technology Announces Second Quarter Fiscal 2008 Results
Date:7/29/2008

>Current assets:

Cash and cash equivalents $64,339 $89,140

Marketable securities, short-term 45,723 38,771

Accounts receivable, net 51,173 44,850

Inventories, net 3,017 2,910

Other current assets 10,132 8,846

Total current assets 174,384 184,517

Property and equipment, net 29,525 25,320

Goodwill and intangible assets, net 9,675 11,093

Other long-term assets 3,585 1,831

Total assets $217,169 $222,761

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $8,965 $9,222

Accrued liabilities 34,708 39,875

Deferred revenues 14,144 12,362

Total current liabilities 57,817 61,459

Other long term liabilities 133 148

Total liabilities 57,950 61,607

Total stockholders' equity 159,219 161,154

Total liabilities and stockholders'

equity $217,169 $222,761

ALIGN TECHNOLOGY, INC.

BUSINESS OUTLOOK SUMMARY

(unaudited)

The outlook figures provided below and elsewhere in this press release are approximate in nature since Align's business outlook is difficult to predict. Align's future performance involves numerous risks and uncertainties and the company's results could differ materially from the outlook provided. Some of the factors that could affect Align's
'/>"/>

SOURCE Align Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Align Technology Executive to Present at Upcoming Financial Conferences
2. WellPoint Announces Realignment of Core Businesses; Names New Executives
3. Align Technology to Announce Third Quarter 2007 Financial Results on October 24, 2007
4. Align Technology, Inc. Earns PACE Approval From Academy of General Dentistry
5. Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study
6. Threshold Pharmaceuticals Announces Corporate Realignment
7. Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology
8. Dallas Among the First to Offer Probiotic Supplement Align(R)
9. McGill researchers link enzyme to breast cancer malignancy
10. Breast Cancer Genes Also Raise Mens Risk for Malignancy
11. iNOS expression may links chronic biliary inflammation to malignant transformation
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Daniel K. Spiegelman Elected to Board of Directors of Omeros 2Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research 2Finally a Health Care Option for Small Businesses 50925 1Finally a Health Care Option for Small Businesses 50925 22009 3A Immunotec announces important clinical research initiative 3A New study to be launched with the goal of improving the quality of the aging pro 12920 12009 3A Immunotec announces important clinical research initiative 3A New study to be launched with the goal of improving the quality of the aging pro 12920 22009 3A Immunotec announces important clinical research initiative 3A New study to be launched with the goal of improving the quality of the aging pro 12920 3Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 1Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 2Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 3Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 4
Other Medicine Technology:Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 2Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 3Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 4Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 5Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 6Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 2Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 3Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 4Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 5Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 6Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 7Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 8Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 9Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 10